Atara Biotherapeutics Inc
ATRAHealthcare|Biotechnology|USA
$9.72
-0.26 (-2.59%)
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04577326 Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma | Malignant Pleural Mesothelioma (MPM) | P1 | Active | 14 | Open-label | cyclophosphamide, CAR T cells |
| NCT03283826 Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis | Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | P1P2 | Terminated | 134 | RCT, Double-blind | ATA188, Placebo |
| NCT03769467 Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms | P1P2 | Terminated | 12 | Open-label | Tabelecleucel, Pembrolizumab |
| NCT00002663 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies | EBV-induced Lymphomas, EBV-associated Malignancies | P1P2 | Completed | 58 | Open-label | Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) |
| NCT01646645 Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation | Cytomegalovirus | P2 | Completed | 58 | Open-label | CMV-pp65 CTLs |
| NCT01498484 Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies | EBV-induced Lymphomas, EBV-associated Malignancies | P2 | Completed | 87 | Open-label | EBV-specific T cells (EBV-CTLs) |
| NCT06256484 A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | P1 | Terminated | 1 | Open-label | ATA3219 |
| NCT06429800 A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus | Lupus Nephritis, Systemic Lupus Erythematosus | P1 | Withdrawn | — | Open-label | ATA3219 |
| NCT00620633 Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | Leukemia, Myelodysplastic Syndrome | P1 | Completed | 22 | Open-label | WT1-sensitized T cells |
| NCT02822495 Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies | Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders | NO_LONGER_AVAILABLE | — | — | tabelecleucel | |
| NCT03010332 Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease | CMV Viremia, CMV Disease | NO_LONGER_AVAILABLE | — | — | Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs) |